-
The elements of performance for the CAUTI prevention safety goal are as follows:
-
The Joint Commission recently posted the following answer to a frequently asked question on screening for methicillin-resistant Staphylococcus aureus (MRSA).
-
On Aug. 10, 2011, the Food and Drug Administration (FDA) approved Complera, a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.
-
-
Atrial fibrillation (AF) is an irregular, disorganized, electrical activity of the atria.1 It is characterized by uncoordinated atrial activity that leads to inefficient atrial contraction and impaired ventricular filling, which leads to hemodynamic and mechanical functional impairments.
-
Interpret the 12-lead ECG shown above obtained from a hemodynamically stable patient with underlying heart disease and new-onset palpitations. Despite the apparent QRS widening is this sinus tachycardia (arrow pointing to 'P waves' in lead II)?
-
-
An ultra long-acting, orally-inhaled beta2-adrenergic agonist (LABA) has been approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol is formulated as a dry powder and is the first beta2-agonist to be dosed once-daily. It is marketed by Novartis as Arcapta™.
-
Duplex ultrasonography should be used in asymptomatic patients with known or suspected carotid arterial stenosis and should be considered for use in asymptomatic patients who have symptomatic peripheral arterial disease, coronary artery disease, or an atherosclerotic aortic aneurysm, and even in the asymptomatic patients who simply are at high cardiovascular risk.
-
Sleep-disordered breathing is a significant risk factor for cognitive decline and continuous positive airway pressure (CPAP) therapy may prevent or slow this process.
